This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
20
New Jersey Medical School
Newark, New Jersey, United States
Rutgers School for Dental Medicine
Newark, New Jersey, United States
University Hospital
Newark, New Jersey, United States
Rowan University
Stratford, New Jersey, United States
Pre-treatment OSCC morphology and PDPN expression
Measure morphology and podoplanin (PDPN) expression by immunohistochemistry of cells included in initial biopsies of oral lesions in comparison to normal oral squamous epithelial cells (OSCCs). We will select patients with lesions that express robust levels of PDPN and notable dysplasia for inclusion in the study.
Time frame: 1 day to 4 weeks.
Post-treatment OSCC morphology and PDPN expression
Evaluate and compare the PDPN expression and morphology of cells from included in resected oral lesions from patients treated with the experimental compound MASL or placebo. We will measure if MASL treatment decreases PDPN expression and normalizes morphology of OSCC cells on a defined scale of pathological examination by immunohistochemistry.
Time frame: 1 day to 4 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.